Regulatory | ApexOnco - Clinical Trials news and analysis

“OncologyPipeline is my favorite CI tool”

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Regulatory

27 November 2024

Cabometyx’s Cabinet committee

Regulatory

27 November 2024

EU backs Tevimbra's stomach restriction – and then some

Regulatory

22 November 2024

Targeted lung cancer niche sees a German pharma battle

But could toxicity be holding back filing plans?

Regulatory

19 November 2024

Jefferies 2024 – Arvinas gets a degrader delay

Regulatory

19 November 2024

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Regulatory

18 November 2024

Syndax gets an early menin nod

Regulatory

14 November 2024

Not so fast for Astra in bladder cancer

Regulatory

12 November 2024

Astra shifts its dato lung focus again

Regulatory

5 November 2024

Sana loses its taste for oncology

Regulatory

1 November 2024

FDA red and green lights: October 2024

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

Subscribe to Regulatory

Cabometyx’s Cabinet committee

EU backs Tevimbra's stomach restriction – and then some

Targeted lung cancer niche sees a German pharma battle

Jefferies 2024 – Arvinas gets a degrader delay

Jefferies 2024 – Nuvation lays out its US taletrectinib strategy

Syndax gets an early menin nod

Not so fast for Astra in bladder cancer

Astra shifts its dato lung focus again

Sana loses its taste for oncology

FDA red and green lights: October 2024

Recent Quick take

Most Popular